Lynparza approved in Japan for 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that Lynparza (olaparib) has been approved in Japan as a…
Read More...
Read More...
